Radiotherapy and immunotherapy: a beneficial liaison?

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Nature Reviews Clinical Oncology

• Publication date

  2017-01-17

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/nrclinonc.2016.211PMID 28094262
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Targeting NK Cells for Anticancer Immunotherapy: Clinical and Preclinical Approaches

  2016cited by this paper
• Radiation Therapy Induces Macrophages to Suppress T-Cell Responses Against Pancreatic Tumors in Mice.

  2016cited by this paper
• The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.

  2016cited by this paper
• Hypofractionated ablative radiotherapy for locally advanced pancreatic cancer

  2016cited by this paper
• Subverting misconceptions about radiation therapy

  2016cited by this paper
• Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects

  2016cited by this paper
• Holland-Frei Cancer Medicine

  2016cited by this paper
• A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab

  2015cited by this paper
• The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients

  2015cited by this paper
• LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective.

  2015cited by this paper
• Stereotactic Body Radiotherapy Results for Pulmonary Oligometastases: A Two-Institution Collaborative Investigation.

  2015cited by this paper
• The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence

  2015cited by this paper
• Abscopal effects of radiation therapy: a clinical review for the radiobiologist.

  2015cited by this paper
• Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial.

  2015cited by this paper
• TH2-Polarized CD4+ T Cells and Macrophages Limit Efficacy of Radiotherapy

  2015cited by this paper
• Radiation and Dual Checkpoint Blockade Activates Non-Redundant Immune Mechanisms in Cancer

  2015cited by this paper
• Myeloid-derived cells in tumors: effects of radiation.

  2015cited by this paper
• Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

  2015cited by this paper
• Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.

  2015cited by this paper
• TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity.

  2015cited by this paper
• Hypofractionated stereotactic body radiotherapy in spinal metastasis - with or without epidural extension.

  2015cited by this paper
• FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis.

  2015cited by this paper
• PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

  2015cited by this paper
• Subversion of anticancer immunosurveillance by radiotherapy

  2015cited by this paper
• In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment.

  2015cited by this paper
• Utilizing Chimeric Antigen Receptors to Direct Natural Killer Cell Activity

  2015cited by this paper
• Enhanced targeting of stem-like solid tumor cells with radiation and natural killer cells

  2015cited by this paper
• Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

  2015cited by this paper
• CDKN1A regulates Langerhans cell survival and promotes Treg cell generation upon exposure to ionizing irradiation

  2015cited by this paper
• Radiation and inflammation.

  2015cited by this paper
• The effect of ionizing radiation on regulatory T cells in health and disease.

  2015cited by this paper
• Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future.

  2015cited by this paper
• The antitumor immune response generated by fractionated radiation therapy may be limited by tumor cell adaptive resistance and can be circumvented by PD-L1 blockade

  2015cited by this paper
• Interferons and the Immunogenic Effects of Cancer Therapy.

  2015cited by this paper
• Regulation of tumor metastasis by myeloid-derived suppressor cells.

  2015cited by this paper
• Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.

  2015cited by this paper
• PD-1 Restrains Radiotherapy-Induced Abscopal Effect

  2015cited by this paper
• Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions

  2015cited by this paper
• Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.

  2015cited by this paper
• Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy

  2015cited by this paper
• Stereotactic radiation therapy combined with immunotherapy: augmenting the role of radiation in local and systemic treatment.

  2015cited by this paper
• NK cells and cancer: you can teach innate cells new tricks

  2015cited by this paper
• Nivolumab in previously untreated melanoma without BRAF mutation.

  2015cited by this paper
• Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected.

  2015cited by this paper
• Relevance of tumor-infiltrating lymphocytes in breast cancer

  2015cited by this paper
• Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.

  2015cited by this paper
• Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

  2014cited by this paper
• PD-1 blockade induces responses by inhibiting adaptive immune resistance

  2014cited by this paper
• Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy

  2014cited by this paper
• Checkpoint Blockade Cancer Immunotherapy Targets Tumour-Specific Mutant Antigens

  2014cited by this paper
• Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.

  2014cited by this paper
• MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

  2014cited by this paper
• Imaging , Diagnosis , Prognosis Prognostic and Predictive Values of the Immunoscore in Patients with Rectal Cancer

  2014cited by this paper
• Radiotherapy-Induced Anti-Tumor Immunity Contributes to the Therapeutic Efficacy of Irradiation and Can Be Augmented by CTLA-4 Blockade in a Mouse Model

  2014cited by this paper
• Kill and spread the word: stimulation of antitumor immune responses in the context of radiotherapy.

  2014cited by this paper
• The Effect of Radiation on the Immune Response to Cancers

  2014cited by this paper
• Type I interferons induced by radiation therapy mediate recruitment and effector function of CD8+ T cells

  2014cited by this paper
• Tolerance and exhaustion: defining mechanisms of T cell dysfunction.

  2014cited by this paper
• Current perspectives on immunotherapy.

  2014cited by this paper
• Targeting the tumor microenvironment with interferon-β bridges innate and adaptive immune responses.

  2014cited by this paper
• Cancer Stem Cell Immunology: Key to Understanding Tumorigenesis and Tumor Immune Escape?

  2014cited by this paper
• Radio‐responsive tumors exhibit greater intratumoral immune activity than nonresponsive tumors

  2014cited by this paper
• Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice.

  2014cited by this paper
• Stereotactic Radiation Therapy Augments Antigen-Specific PD-1–Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen

  2014cited by this paper
• A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates

  2014cited by this paper
• Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade.

  2014cited by this paper
• Protons and more: state of the art in radiotherapy.

  2014cited by this paper
• Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death

  2014cited by this paper
• Tumor-associated macrophages: from mechanisms to therapy.

  2014cited by this paper
• STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors.

  2014cited by this paper
• Role of Radiation Therapy in Inducing Antigen Specific Antitumor Immune Responses When Combined With Anti-PD1 Checkpoint Blockade: Mechanism and Clinical Implications

  2014cited by this paper
• STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors.

  2014cited by this paper
• Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial

  2014cited by this paper
• Effects of Single or Combined Treatments with Radiation and Chemotherapy on Survival and Danger Signals Expression in Glioblastoma Cell Lines

  2014cited by this paper
• Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing

  2014cited by this paper
• Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.

  2014cited by this paper
• Cancer: Antitumour immunity gets a boost

  2014cited by this paper
• New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape.

  2014cited by this paper
• Many faces of DAMPs in cancer therapy

  2013cited by this paper
• Combining radiotherapy and cancer immunotherapy: a paradigm shift.

  2013cited by this paper
• Microenvironmental regulation of tumor progression and metastasis

  2013cited by this paper
• Resveratrol Inhibits Ionising Irradiation-Induced Inflammation in MSCs by Activating SIRT1 and Limiting NLRP-3 Inflammasome Activation

  2013cited by this paper
• Tumor necrosis factor-α blocks differentiation and enhances suppressive activity of immature myeloid cells during chronic inflammation.

  2013cited by this paper
• Radiation as an immune modulator.

  2013cited by this paper
• Low-dose irradiation programs macrophage differentiation to an iNOS⁺/M1 phenotype that orchestrates effective T cell immunotherapy.

  2013cited by this paper
• The abscopal effect associated with a systemic anti-melanoma immune response.

  2013cited by this paper
• Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study.

  2013cited by this paper
• In Situ Observation of the Effects of Local Irradiation on Cytotoxic and Regulatory T Lymphocytes in Cervical Cancer Tissue

  2013cited by this paper
• Pivotal Roles of cGAS-cGAMP Signaling in Antiviral Defense and Immune Adjuvant Effects

  2013cited by this paper
• A randomized hypofractionation dose escalation trial for high risk prostate cancer patients: interim analysis of acute toxicity and quality of life in 124 patients

  2013cited by this paper
• Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma.

  2013cited by this paper
• Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment.

  2013cited by this paper
• Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial.

  2013cited by this paper
• Exploiting the stress response to radiation to sensitize poorly immunogenic tumors to anti-CTLA-4 treatment

  2013cited by this paper
• Immune Modulation and Stereotactic Radiation: Improving Local and Abscopal Responses

  2013cited by this paper
• CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer.

  2013cited by this paper
• Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: toxicity, biochemical, and pathological outcomes.

  2013cited by this paper
• IFN-γ mediates the antitumor effects of radiation therapy in a murine colon tumor.

  2013cited by this paper
• Extracranial oligometastases: a subset of metastases curable with stereotactic radiotherapy.

  2013cited by this paper
• Effects of Adjuvant Chemoradiotherapy on the Frequency and Function of Regulatory T Cells in Patients with Head and Neck Cancer

  2013cited by this paper

• Citraconic acid mitigates radiation-induced intestinal injury by modulating IL-17 signaling to enhance epithelial regeneration.

  2026cites this paper
• Integrated Radiotherapy with Immune-Chemotherapy for Unresectable Biliary Tract Cancer: An Exploratory Pilot Study.

  2026cites this paper
• Tumor ecosystem and microbiome features associated with efficacy and resistance to avelumab plus chemoradiotherapy in head and neck cancer

  2026cites this paper
• An organolutetium nanosensitizer synergizes with PARP inhibition to unleash STING-mediated immunity for low-dose radioimmunotherapy

  2026cites this paper
• X-ray activated platinum complex induces DNA damage and enhances cancer immunotherapy through abscopal effect.

  2026cites this paper
• STING agonist-loaded cationic radioactive microspheres enhance transarterial radioembolization of hepatocellular carcinoma via tumor immune activation.

  2026cites this paper
• Early effects of ionizing radiation on molecular modifications and hallmarks of Immunogenic cell death in mouse tumor cells.

  2026cites this paper
• Radiation-induced interferon-I response impairs thyroid organoid function

  2026cites this paper
• CD20-Targeted α-Radionuclides Synergize with Immune Checkpoint Inhibition to Treat Murine Lymphoma.

  2026cites this paper
• A TP53-Pathway-Based Prognostic Signature for Radiotherapy and Functional Validation of TP53I3 in Non-Small-Cell Lung Cancer

  2026cites this paper
• A Retrospective Study on the Clinical Characteristics and Management of Immune-Related Adverse Events in Gynecologic Cancer Patients Treated with Immune Checkpoint Inhibitors

  2026cites this paper
• Mapping the Research Landscape of the Correlation Between Radiotherapy and Tumor Immune Microenvironment: A Bibliometric Analysis

  2026cites this paper
• Systemic Immunity Triggered by Boron Neutron Capture Therapy via Manganese-Borate Complex.

  2026cites this paper
• Naxitamab with novel scheduling and stepped-up dosing of GM-CSF plus vaccine, but no myeloablative therapy for patients with high-risk neuroblastoma in first complete remission.

  2026cites this paper
• Reprogramming the tumor immune microenvironment in cervical cancer: synergy between radiotherapy and immunotherapy.

  2026cites this paper
• Radiotherapy for more efficacious novel anticancer drugs: a position paper from the European Society for Radiotherapy and Oncology (ESTRO) focus group on novel systemic therapies and radiotherapy.

  2026cites this paper
• Spatial Confinement of Platinum Nanoclusters in a Photoactive Metal-Organic Framework for Radiotherapy Enhancement and Redox-Mediated Immune Activation.

  2026cites this paper
• Orthogonally Engineered Bacteria Capture Metabolically Labeled Tumor Antigens to Improve the Systemic Immune Response in Irradiated Tumors.

  2025cites this paper
• Provoking cancer cell cuproptosis breaks radiotherapy resistance

  2025cites this paper
• A Phase 2 Study of Sotigalimab, a CD40 Agonist Antibody, plus Concurrent Chemoradiation as Neoadjuvant Therapy for Esophageal and Gastroesophageal Junction Cancers

  2025cites this paper
• A cascade-regulated nanoadjuvant for antigen oxidation and capture to potentiate in-situ cancer vaccination.

  2025cites this paper
• Radiotherapy increases circulating early-stage natural killer cells with enhanced cytokine responsiveness in breast cancer.

  2025cites this paper
• Engineered liposomal nanoplatforms for precise cancer immunotherapy: advancing biomedical innovations

  2025cites this paper
• Radiotherapy induces YTHDF2 in dendritic cells impairing cross-presentation and T cell function.

  2025cites this paper
• TREX1, a predator for treating MSI‐H tumors?

  2025cites this paper
• Dual PI3Kδ/γ inhibition enhances radiotherapy-induced antitumor immunity via macrophage-dependent cGAS-STING-type I interferon signaling.

  2025cites this paper
• Systematic review on the safety and efficacy of immune checkpoint inhibitors combined with stereotactic body radiotherapy in advanced pancreatic cancer

  2025cites this paper
• Advances in the combination of immunotherapy and radiotherapy for microsatellite-stable metastatic colorectal cancer

  2025cites this paper
• Cancer vaccines: platforms and current progress

  2025cites this paper
• Efficacy of Anti-Cancer Immune Responses Elicited Using Tumor-Targeted IL-2 Cytokine and Its Derivatives in Combined Preclinical Therapies

  2025cites this paper
• Efficacy of Radiotherapy Combined with Immunotherapy in MSS/pMMR Metastatic Colorectal Cancer: a Propensity-Matched Retrospective Study

  2025cites this paper
• Efficacy of metastatic lesion radiotherapy in de novo metastatic nasopharyngeal carcinoma patients receiving local regional radiotherapy and chemo-immunotherapy: a multicenter retrospective study.

  2025cites this paper
• SLAMF1 expression in breast cancer cells delays tumor growth in vivo

  2025cites this paper
• Tumors with microsatellite instability upregulate TREX1 to escape antitumor immunity.

  2025cites this paper
• Exploring Strategies for Personalized Radiation Therapy: Part III Identifying genetic determinants for Radiation Response with Meta Learning

  2025cites this paper
• Management outcomes for biopsy-proven radiation necrosis in patients with brain metastases in the era of immune-checkpoint blockade

  2025cites this paper
• Adjuvant Chemoradiation and Immunotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Cancer: A Randomized Clinical Trial.

  2025cites this paper
• Immunotherapy combined with radiotherapy for advanced non-small cell lung cancer: Current status and challenge (Review)

  2025cites this paper
• Engineered Magnetic Resonance Nanoprobes for Visualizing Tumor Programmed Cell Death Ligand 1 Level and Enhancing Synergistic Radio Immunotherapy.

  2025cites this paper
• Precision targeting of rhabdomyosarcoma by combining primary CAR NK cells and radiotherapy

  2025cites this paper
• Immunotherapy combined with radiotherapy in the treatment of lung cancer: a meta-analysis of therapeutic effectiveness, safety considerations, and abscopal effect

  2025cites this paper
• PROCR diminishes the efficacy of radiation by impairing T-cell-mediated antitumour immunity

  2025cites this paper
• From trash to treasure: tumor draining lymph nodes as a multi-omics goldmine in cancer therapy

  2025cites this paper
• Low‐Dose X‐Ray Radiation Enhances Intratumoral Accumulation and Antitumor Effects of Nanoscale Coordination Polymers via Neutrophil‐Mediated Trafficking

  2025cites this paper
• Development of combinatorial immunotherapy for patients with advanced gastric cancer from the perspective of immunosuppressive mechanisms in the tumor microenvironment

  2025cites this paper
• How histone modifications influence cellular radiosensitivity: Pharmaceutically targeting epigenetic regulators as a promising avenue to overcome radioresistance

  2025cites this paper
• Efficacy of local consolidative radiotherapy with first-line chemoimmunotherapy in synchronous oligometastatic esophageal squamous cell carcinoma

  2025cites this paper
• RPL29 as a radiotherapy-sensitive prognostic biomarker in multiple myeloma

  2025cites this paper
• Radiation Without Borders: Unraveling Bystander and Non-Targeted Effects in Oncology

  2025cites this paper
• Transactions on micronuclear DNA and implications for immune signaling.

  2025cites this paper
• Exploiting the endothelial-immune axis to improve radiotherapy efficacy.

  2025cites this paper
• Naxitamab plus stepped-up dosing of granulocyte–macrophage colony-stimulating factor for primary refractory high-risk neuroblastoma: results of a phase I/II trial

  2025cites this paper
• Efficacy of metastasis-directed therapy in de novo metastatic nasopharyngeal carcinoma patients receiving chemo-immunotherapy and local regional radiotherapy: a multicenter retrospective study

  2025cites this paper
• Patient-Derived Organoids as a Platform to Decipher and Overcome Radioresistance: From the Tumor Microenvironment to Radiosensitizer Discovery

  2025cites this paper
• Radiation-induced amphiregulin drives tumour metastasis

  2025cites this paper
• A γ-ray responsive hydrogel “blasting fuse” for prevention of postoperative breast cancer recurrence and metastasis via radio-immunotherapy

  2025cites this paper
• Advances and challenges in cancer immunotherapy: Strategies for personalized treatment.

  2025cites this paper
• Facts and hopes in radioimmunotherapy of oligometastatic disease.

  2025cites this paper
• Nitric Oxide‐Releasing Nanoscale Metal‐Organic Layer Overcomes Hypoxia and Reactive Oxygen Species Diffusion Barriers to Enhance Cancer Radiotherapy

  2025cites this paper
• Co-activating STING-TLR9 pathways promotes radiotherapy-induced cancer vaccination.

  2025cites this paper
• NVP-AUY922 relieves radiation-induced intestinal injury via regulating EPHX1.

  2025cites this paper
• Peripheral blood PD-1+ T lymphocytes as biomarkers in liquid biopsies for solid tumors: Clinical significance and prognostic applications.

  2025cites this paper
• The clinical significance and potential therapeutic target of tumor-associated macrophage in non-small cell lung cancer

  2025cites this paper
• YTHDFs as radiotherapy checkpoints in tumor immunity.

  2025cites this paper
• Radiotherapy is enhanced by CPH:SA IL-1α microparticles in a murine HNSCC tumor model

  2025cites this paper
• Porphyrin-Engineered 125I-Nanoseeds as a Prototype for Immunogenic Brachytherapy.

  2025cites this paper
• Breaking the barriers in effective and safe toll-like receptor stimulation via nano-immunomodulators for potent cancer immunotherapy.

  2025cites this paper
• Advances in PSMA-Targeted Radionuclide Therapeutics

  2025cites this paper
• Cancer-Associated Fibroblasts as the “Architect” of the Lung Cancer Immune Microenvironment: Multidimensional Roles and Synergistic Regulation with Radiotherapy

  2025cites this paper
• Spatially precise chemo-radio-immunotherapy by antibody drug conjugate directed tumor radiosensitization to potentiate immunotherapies

  2025cites this paper
• Efficacy and safety of radiotherapy combined with immune checkpoint inhibitors for advanced or unresectable hepatocellular carcinoma: a systematic review and meta-analysis.

  2025cites this paper
• Evolutionary Double-Bind Treatment Using Radiation Therapy and Natural Killer Cell-Based Immunotherapy in Prostate Cancer

  2025cites this paper
• Nanotherapeutic Wee1 Inhibition Sensitizes Tumor Ferroptosis to Promote Cancer Immunotherapy and Abscopal Effect.

  2025cites this paper
• Unlocking the Potential of Disulfidptosis: Nanotechnology-Driven Strategies for Advanced Cancer Therapy.

  2025cites this paper
• Advances in cancer immunotherapy: historical perspectives, current developments, and future directions

  2025cites this paper
• TIGIT blockade increases efficacy of PD-1 blockade combined with radiation therapy in triple-negative breast cancer model.

  2025cites this paper
• Single-arm phase II study of consolidation serplulimab following hypofractionated radiotherapy with concurrent chemotherapy for patients with limited stage small-cell lung cancer: ASTRUM-LC01 study protocol

  2025cites this paper
• Updates on radiotherapy-immunotherapy combinations: Proceedings of 8th Annual ImmunoRad Conference

  2025cites this paper
• Rechallenge with immune-checkpoint inhibitors in patients with advanced-stage lung cancer

  2025cites this paper
• Stereotactic body radiation therapy (SBRT) increases anti-PD-1 antitumor activity by enhancing the tumor immune microenvironment in mice with metastatic hepatocellular carcinoma

  2025cites this paper
• Establishment of whole tumor cell antigen-induced cellular immunotherapy for lung adenocarcinoma

  2025cites this paper
• Applicability of cCR assessment criteria in pMMR rectal cancer patients treated with neoadjuvant chemoradiotherapy combined with immunotherapy

  2025cites this paper
• Additions and subtractions of radiotherapy in patients with oligometastatic non-small cell lung cancer under the era of immunotherapy.

  2025cites this paper
• Advances in radiotherapy for mouth neoplasms: emerging technologies and future perspectives

  2025cites this paper
• Investigating hypoxia-inducible factor signaling in cancer: Mechanisms, clinical implications, targeted therapeutic strategies, and resistance.

  2025cites this paper
• Mitophagy: A key regulator of radiotherapy resistance in the tumor immune microenvironment.

  2025cites this paper
• Hybrid-Ligand Metal-Organic Frameworks Enabling Radio-Radiodynamic-Chemodynamic Therapy Primes Checkpoint Blockade Immunotherapy in Hypoxic Tumors.

  2025cites this paper
• Photon and particle radiotherapy induce redundant modular chemotaxis of human lymphocytes

  2025cites this paper
• Durvalumab after radiotherapy in patients with unresectable stage III non-small-cell lung cancer ineligible for chemotherapy: the DUART phase II nonrandomized controlled study

  2025cites this paper
• THERAPEUTIC OPTIONS FOR ELDERLY PATIENTS WITH LOCALLY ADVANCED HEAD AND NECK CANCERS: PRINCIPLES OF GERIATRIC ONCOLOGY

  2025cites this paper
• Addressing clinical needs in NSCLC immunotherapy: Mechanisms of resistance and promising combination strategies

  2025cites this paper
• Cancer Immunotherapy in Combination with Radiotherapy and/or Chemotherapy: Mechanisms and Clinical Therapy

  2025cites this paper
• Immunotherapy in Head and Neck Cancer.

  2025cites this paper
• Patterns of immunity changes predict response to stereotactic ablative radiotherapy in early non-small-cell lung cancer.

  2025cites this paper
• A customizable 32P hydrogel applicator for brachytherapy of skin hemangioma based on machine learning and 3D-printing.

  2025cites this paper
• The Influencing Factors of Radiation Pneumonia in Lung Cancer Patients Undergoing Radiotherapy

  2025cites this paper
• In situ genetically engineering nanosystem for reversing immunosuppression of cancer-associated fibroblasts in breast cancer radiotherapy.

  2025cites this paper
• Intracellular Disulfide Stress Induced Actin Dysfunction for Enhancing Radiotherapy Sensitivity and Eliciting Antitumor Immunity.

  2025cites this paper
• Targeting GOLPH3L improves glioblastoma radiotherapy by regulating STING-NLRP3-mediated tumor immune microenvironment reprogramming.

  2025cites this paper
• Phase 2 Trial of Combination Radiotherapy and Pembrolizumab Plus Chemotherapy in Patients With Previously Untreated Metastatic NSCLC: NJLCG 1902

  2025cites this paper